Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, H1 2014, New Report Launched

‘Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 67 pages, “Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, H1 2014” report covered 5 companies – Bristol-Myers Squibb Company, Johnson & Johnson, Biocon Limited, Italfarmaco S.p.A., Avesthagen Limited.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/systemic-juvenile-idiopathic-arthritis-sjia-pipeline-review-h1-2014

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2014, New Report Launched

Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2014′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .
  • A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA) .
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 103 pages, “Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2014” report covered 14 companies – Genzyme Corporation, F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Pfizer Inc., Paratek Pharmaceuticals, Inc., Neurotune AG Trophos SA, Nexgenix Pharmaceuticals, LLC, Genethon Vybion, Inc., California Stem Cell, Inc., OrphageniX, Inc., Retrophin, LLC, Neuro

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/spinal-muscular-atrophy-sma-pipeline-review-h1-2014   

Find All Pharma and Healthcare Reports at:- http://www.marketresearchreports.com/pharma-healthcare  

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Primary Dysmenorrhea – Pipeline Review, H1 2014, New Report Launched

‘Primary Dysmenorrhea – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Primary Dysmenorrhea.
  • A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Primary Dysmenorrhea pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 39 pages, “Primary Dysmenorrhea – Pipeline Review, H1 2014” report covered 3 companies – Merck & Co., Inc., PDC Biotech GmbH, Jiangsu Kanion Pharmaceutical Co., Ltd.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/primary-dysmenorrhea-pipeline-review-h1-2014

Find All Pharma and Healthcare Reports at:- http://www.marketresearchreports.com/pharma-healthcare 

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

MedImmune, LLC – Product Pipeline Review – 2014, New Report Launched

“MedImmune, LLC – Product Pipeline Review – 2014” provides data on the MedImmune, LLC’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Publisher’s proprietary databases, MedImmune, LLC’s corporate website, SEC filings, investor presentations and featured press releases, both from MedImmune, LLC and industry-specific third party sources, put together by Publisher’s team.

Scope

  • MedImmune, LLC – Brief MedImmune, LLC overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of MedImmune, LLC human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of MedImmune, LLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the MedImmune, LLC’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate MedImmune, LLC’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of MedImmune, LLC in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the MedImmune, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with MedImmune, LLC.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of MedImmune, LLC and identify potential opportunities in those areas.

Spanning over 106 pages, 27 tables and 10 figures “MedImmune, LLC – Product Pipeline Review – 2014” report covering the MedImmune, LLC Snapshot, MedImmune, LLC Overview, MedImmune, LLC – Pipeline Review, MedImmune, LLC – Pipeline Analysis, MedImmune, LLC – Key Manufacturing Facilities, Appendix.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/medimmune-llc-product-pipeline-review-2014

Find All Company Reports (Pharma and Healthcare) Reports at:- http://www.marketresearchreports.com/company-reports-pharma-healthcare

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Genentech, Inc. Product Pipeline Review – 2014, New Report Launched

“Genentech, Inc. – Product Pipeline Review – 2014” provides data on the Genentech, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Publisher’s proprietary databases, Genentech, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Genentech, Inc. and industry-specific third party sources, put together by Publisher’s team.

Scope

  • Genentech, Inc. – Brief Genentech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Genentech, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Genentech, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Genentech, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Genentech, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Genentech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Genentech, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Genentech, Inc. and identify potential opportunities in those areas.

Spanning over 136 pages, 25 tables and 11 figures “Genentech, Inc. – Product Pipeline Review – 2014” report covering the Genentech, Inc. Snapshot, Genentech, Inc. Overview, Genentech, Inc. – Research and Development Overview, Genentech, Inc. – Pipeline Analysis, Genentech, Inc. – Key Manufacturing Facilities, Appendix.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/genentech-inc-product-pipeline-review-2014

Find All Company Reports (Pharma and Healthcare) Reports at:- http://www.marketresearchreports.com/company-reports-pharma-healthcare

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H1 2014, New Report Launched

‘Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 67 pages, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H1 2014” report covered 5 companies – Merck & Co., Inc., ReGenX Biosciences, LLC, Cerenis Therapeutics SA, Amgen Astellas BioPharma K.K., Biospherics.net Incorporated

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-pipeline-review-h-0   

Find All Pharma and Healthcare Reports at:- http://www.marketresearchreports.com/pharma-healthcare 

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) – Pipeline Review, H1 2014, New Report Launched

‘Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease). Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease).
  • A review of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 63 pages, “Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) – Pipeline Review, H1 2014” report covered 3 companies – Isis Pharmaceuticals, Inc., Pfizer Inc., Alnylam Pharmaceuticals, Inc., SOM Biotech SL

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-2

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Bone Marrow Transplantation – Pipeline Review, H1 2014, New Report Launched

‘Bone Marrow Transplantation – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Bone Marrow Transplantation – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Bone Marrow Transplantation.
  • A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 60 pages, “Bone Marrow Transplantation – Pipeline Review, H1 2014” report covered 5 companies – Mesoblast Limited, Cleveland BioLabs, Inc., Pluristem Therapeutics Inc., Spectrum Pharmaceuticals, Inc., TikoMed AB

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/bone-marrow-transplantation-pipeline-review-h1-2014

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at:http://www.marketresearchreports.com/subscribe-to-newsletter

Batten Disease – Pipeline Review, H1 2014, New Report Launched

‘Batten Disease – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Batten Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Batten Disease. Batten Disease – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

  • A snapshot of the global therapeutic scenario for Batten Disease.
  • A review of the Batten Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Batten Disease pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Batten Disease.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Batten Disease pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 44 pages, “Batten Disease – Pipeline Review, H1 2014” report covered 3 companies – BioMarin Pharmaceutical Inc., ReGenX Biosciences, LLC, Seneb BioSciences, Inc.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/batten-disease-pipeline-review-h1-2014  

Find All Pharma and Healthcare Reports at:- http://www.marketresearchreports.com/pharma-healthcare 

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Lung Transplantation – Pipeline Review, H1 2014, New Report Launched

‘Lung Transplantation – Pipeline Review, H1 2014’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Lung Transplantation – Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Lung Transplantation.
  • A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Lung Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 44 pages, “Lung Transplantation – Pipeline Review, H1 2014” report covered 5 companies – Quark Pharmaceuticals, Inc., Vectura Group plc, Proteo, Inc., APT Pharmaceuticals, Inc. (Inactive), Neopharm Ltd.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/lung-transplantation-pipeline-review-h1-2014

Find All Diseases Reports at:- http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.

MarketResearch Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter